Pichia Patents (Class 435/254.23)
-
Publication number: 20140286934Abstract: The present invention relates to humanized antibodies or fragments thereof that bind to human CD19. More specifically, the present invention relates to a humanized antibody or fragment thereof that binds to human CD19 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 27, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 29; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 31 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 32.Type: ApplicationFiled: January 30, 2014Publication date: September 25, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Stanislas BLEIN, Darko Skegro, Christophe Debonneville, Martin Bertschinger
-
Publication number: 20140287471Abstract: The present disclosure relates to variant CBH I polypeptides that have reduced product inhibition, and compositions, e.g., cellulase compositions, comprising variant CBH I polypeptides. The variant CBH I polypeptides and related compositions can be used in variety of agricultural and industrial applications. The present disclosure further relates to nucleic acids encoding variant CBH I polypeptides and host cells that recombinantly express the variant CBH I polypeptides.Type: ApplicationFiled: October 5, 2012Publication date: September 25, 2014Applicant: Bp Corporation North America Inc.Inventors: Sarah Richardson Hanson, Justin T. Stege, Cecilia Cheng, Peter Luginbuhl
-
Publication number: 20140287465Abstract: The present invention relates to polypeptides having xylanase activity, catalytic domains, and carbohydrate binding domains, and polynucleotides encoding the polypeptides, catalytic domains, and carbohydrate binding domains. The present invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains, and carbohydrate binding domains.Type: ApplicationFiled: December 18, 2012Publication date: September 25, 2014Inventors: Nikolaj Spodsberg, Tarana Shaghasi
-
Publication number: 20140287445Abstract: A flavin-binding glucose dehydrogenase (FAD-GDH), which in addition to having high substrate specificity and adequate desirable heat stability, is suitable for efficient production, preferably using E. coli, yeast or molds and the like as host cells. The FAD-GDH has amino acid substitutions at positions equivalent to one or more locations selected from the group consisting of position 213, position 368 and position 526 in the amino acid sequence described in SEQ ID NO: 8. The FAD-GDH is acquired from a culture by inserting a gene encoding the FAD-GDH into host cells such as E. coli. A preferable example of the FAD-GDH is FAD-GDH, in which a signal peptide region present in an N-terminal region has been deleted from the amino acid sequence of Mucor-derived FAD-GDH, and which has the aforementioned amino acid substitutions. The FAD-GDH can be preferably used in clinical diagnosis.Type: ApplicationFiled: June 6, 2012Publication date: September 25, 2014Inventors: Ryoko Tajima, Kozo Hirokawa, Eriko Yoshihara, Yasuko Tanabe
-
Publication number: 20140288008Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: ApplicationFiled: March 13, 2014Publication date: September 25, 2014Applicants: Daiichi Sankyo Company, Limited, Pieris AGInventors: GABRIELE MATSCHINER, CHRISTINE ROTHE, ANDREAS HOHLBAUM, ANDREA ALLERSDORFER, RACHIDA SIHAM BEL AIBA, MARLON HINNER, ALEXANDER WIEDENMANN, SHINJI YAMAGUCHI, TAKAHIDE ABURATANI, RYUJI HASHIMOTO, TOHRU TAKAHASHI, CHIKAKO NAGASAKI, FUTOSHI NARA, TOMOHIRO NISHIZAWA
-
Publication number: 20140289905Abstract: Provided are isolated polypeptides having xylanase activity, catalytic domains and cellulose binding domains, and polynucleotides encoding the polypeptides, catalytic domains or cellulose binding domains. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or cellulose binding domains.Type: ApplicationFiled: November 9, 2012Publication date: September 25, 2014Applicant: Novozymes Inc.Inventors: Yu Zhang, Junxin Duan, Ye Liu, Lan Tang
-
Publication number: 20140287463Abstract: The present invention relates to novel engineered Pichia strains with improved fermentation yields for expressing heterologous proteins with improved N-glycosylation quality, as well as to methods of generating such strains.Type: ApplicationFiled: October 24, 2012Publication date: September 25, 2014Inventors: Ming-Tang Chen, Byung-Kwon Choi
-
Publication number: 20140275487Abstract: The present invention relates to the field of G protein coupled receptor (GPCR) structural biology and signaling. In particular, the present invention relates to binding domains directed against and/or specifically binding to GPCR:G protein complexes. Also provided are nucleic acid sequences encoding such binding domains and cells expressing or capable of expressing such binding domains. The binding domains of the present invention can be used as universal tools for the structural and functional characterization of G-protein coupled receptors in complex with downstream heterotrimeric G proteins and bound to various natural or synthetic ligands, for investigating the dynamic features of G protein activation, as well as for screening and drug discovery efforts that make use of GPCR:G protein complexes.Type: ApplicationFiled: June 21, 2012Publication date: September 18, 2014Inventors: Jan Steyaert, Els Pardon, Toon Laeremans, Brian Kobilka, Søren Rasmussen, Sébastien Granier, Roger K. Sunahara
-
Publication number: 20140272932Abstract: The present disclosure relates to polypeptides, including fusions thereof, nucleic acids, vectors, host cells, immunodiagnostic reagents, kits, and immunoassays for use detecting the presence of HCV antibodies. More specifically, the present invention describes specific NS3 antigens that can be used for the detection of anti-HCV antibodies.Type: ApplicationFiled: December 23, 2013Publication date: September 18, 2014Applicant: Abbott LaboratoriesInventors: A. Scott Muerhoff, Christopher Marohnic, Larry Birkenmeyer, John Prostko, Felisha Bogdan, Robin Gutierrez
-
Publication number: 20140273110Abstract: Bacteria that run the beta oxidation cycle in reverse anabolic direction are provided, along with many novel primers to start the reverse cycle, pathways to make such primers, and a large variety of products produced thereby. Methods for making desired product by using such primers in the reverse pathway are also disclosed.Type: ApplicationFiled: March 6, 2014Publication date: September 18, 2014Applicant: William Marsh Rice UniversityInventors: Ramon GONZALEZ, James M. CLOMBURG
-
Publication number: 20140274782Abstract: Methyl-lysine affinity reagents created by engineering the 3×MBT methyl-lysine binding domain repeat of lethal (3) malignant brain tumor-like protein 1 (L3MBTL1) are disclosed. In particular, the invention relates to affinity reagents and affinity chromatography media comprising the 3×MBT domain repeat and methods of using such affinity reagents in detection, purification, and proteomic profiling of methylated proteins and peptides.Type: ApplicationFiled: March 15, 2014Publication date: September 18, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Scott M. Carlson, Or Gozani, Kaitlyn E. Moore
-
Publication number: 20140271459Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for HGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-HGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-HGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-HGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with HGF.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: ALDERBIO HOLDINGS LLCInventors: Benjamin H. Dutzar, Katie Anderson, Brian R. Kovacevich, Andrew L. Feldhaus, John A. Latham, Leon F. Garcia-Martinez
-
Publication number: 20140274761Abstract: The invention relates to an isolated nucleic acid sequence comprising a promoter, which is a native sequence of Pichia pastoris comprising the nucleic acid sequence of pCS1 of SEQ ID NO:1, or a functionally active variant thereof which is a size variant, a mutant or hybrid of SEQ ID NO:1, or a combination thereof, expression constructs and recombinant host cells comprising the promoter, and a method of producing a protein of interest under the control of the promoter. It further relates to a method to identify a constitutive promoter from eukaryotic cells, and an isolated nucleic acid sequence comprising a promoter which when operatively linked to a nucleotide sequence encoding a protein of interest directs the expression thereof in a host cell at an expression level that is higher than under control of the native pGAP promoter at high and low growth rates.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: LONZA LTDInventors: Diethard Mattanovich, Brigitte Gasser, Roland Prielhofer
-
Publication number: 20140271623Abstract: Antibody variants having decreased or increased ability to mediate CDC due to modifications at the C-terminus of their heavy chains are described. Methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of said antibodies are also described.Type: ApplicationFiled: July 6, 2012Publication date: September 18, 2014Applicant: GENMAB A/SInventors: Paul Parren, Patrick Van Berkel, Ewald T.J. Van Den Bremer
-
Publication number: 20140271464Abstract: The present invention is directed to antibodies and fragments thereof (especially chimeric and humanized) having binding specificity for HGF and their use in therapy and diagnosis. These antibodies inhibit or block HGF-associated activities including HGF's effects on cell proliferation, invasion, angiogenesis, metastasis and fibrosis. Particularly the antibodies may be used as a monotherapy or in combination therapies in treating cancer, other proliferative disorders and other conditions wherein inhibition of HGF and/or the HGF/HGF-R (c-met) interaction is desired.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: Alderbio Holdings LLCInventors: Leon F. GARCIA-MARTINEZ, Andrew L. Feldhaus, Katie Anderson, Benjamin H. Dutzar, John A. Latham
-
Publication number: 20140273129Abstract: Provided herein are glycerol-3-phosphate dehydrogenase (GPD) enzymes with increased KM for NADH and GPD enzymes with substantially the same affinity for NADH and NADPH and/or are feedback inhibited by glycerol-3-phosphate. Also provided herein are recombinant microorganisms comprising a heterologous gene encoding GPD and a deletion or disruption in an endogenous gene encoding GPD. Also provided are recombinant microorganisms comprising a heterologous gene encoding GPD and a butanol biosynthetic pathway. Further provided are methods of producing butanol comprising providing the recombinant microorganisms described herein and contacting the recombinant microorganism with at least one fermentable carbon substrate under conditions wherein butanol is produced.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: BUTAMAX ADVANCED BIOFUELS LLCInventors: Ritu Bhalla, Gopal K. Chotani, Michael Dauner, Mark J. Nelson, Daniel P. O'keefe, Caroline M. Peres, Jahnavi Chandra Prasad, Jean-Francois Tomb
-
Publication number: 20140273089Abstract: The present invention provides Fibroblast Growth Factor Receptor-Like (FGFR-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGFR-L polypeptides. The inventio further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with FGFR-L polypeptides.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Applicant: AMGEN, INC.Inventors: Christiaan M. Saris, Sharon X. Mu, Min Xia, Thomas Charles Boone, Todd Covey
-
Publication number: 20140275490Abstract: [Problem] An object of the present invention is to provide an anti-human IL-23R antibody having excellent activity and/or cross-reactivity compared to conventional IL-23R antibodies, and means for using the antibody to prevent or treat various diseases in which human IL-23R is involved in pathogenesis. [Means for Solution] An anti-human IL-23R antibody comprising a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:5, 9, 13, 17, 21, 25 or 29 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:7, 11, 15, 19, 23, 27 or 31.Type: ApplicationFiled: March 30, 2012Publication date: September 18, 2014Applicant: Astellas Pharma Inc.Inventors: Makoto Ohori, Takanori Sasaki, Hiromu Sato, Katsunari Taguchi
-
Publication number: 20140255997Abstract: The present invention relates to glucoamylase variants having improved thermostability. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: ApplicationFiled: October 11, 2012Publication date: September 11, 2014Inventors: Esben Peter Friis, Leonardo De Maria, Jesper Vind, Thomas A. Poulsen, Allan Svendsen, Steffen Danielsen, Rolf T. Lenhard, Henrik Friis-Madsen, Lars K. Skov
-
Publication number: 20140256930Abstract: An object of the present invention is to provide a method for converting the coenzyme dependency of enzymes of the medium-chain dehydrogenase/reductase (MDR) family. A further object of the present invention is to provide enzyme variants of the MDR family whose coenzyme dependency is converted by the conversion method and a method for enzymatically producing optically active alcohols using the enzymes. The present inventors developed a novel enzyme conversion method for converting the coenzyme dependency of enzymes of the MDR family, rationally designed enzyme variants that are altered by the enzyme conversion method to be able to use NADPH as a coenzyme from a useful enzyme of the MDR family that uses NADH as a coenzyme, and actually provide variants having such an ability.Type: ApplicationFiled: June 27, 2012Publication date: September 11, 2014Applicant: KANEKA CORPORATIONInventors: Shinichi Yoshida, Shunichi Taira, Masakatsu Nishihachijyo, Masutoshi Nojiri, Shigeru Kawano
-
Publication number: 20140256009Abstract: Described is a method for the enzymatic production of butadiene which allows to produce butadiene from crotyl alcohol. Also described are enzyme combinations and compositions containing such enzyme combinations which allow the enzymatic conversion of crotyl alcohol into butadiene. Furthermore, the invention relates to microorganisms which have been genetically modified so as to be able to produce butadiene from crotyl alcohol. Moreover, the invention relates to a method for the enzymatic production of crotyl alcohol from crotonyl-Coenzyme A. The obtained crotyl alcohol can be further converted into butadiene as described herein. Also described are enzyme combinations which allow to convert crotonyl-Coenzyme A into crotyl alcohol as well as (micro)organisms which express such enzyme combinations.Type: ApplicationFiled: October 18, 2012Publication date: September 11, 2014Applicant: SCIENTIST OF FORTUNE, S.A.Inventor: Philippe Marliere
-
Publication number: 20140255302Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.Type: ApplicationFiled: March 28, 2014Publication date: September 11, 2014Applicant: Teva Pharmaceuticals Australia Pty LtdInventors: Lynn Dorothy Poulton, Adam Clarke, Andrew James Pow, Debra Tamvakis, George Kopsidas, Anthony Gerard Doyle, Philip Anthony Jennings, Matthew Pollard
-
Publication number: 20140248283Abstract: The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of HER2. The present invention also includes an antibody or antibody fragment that is capable of reducing the activity of HER2 in at least one form, including a soluble form or a secreted form. The present invention further includes chimeric antibodies, processes for producing monoclonal and chimeric antibodies or monoclonal or chimeric antibodies, and their therapeutic uses, particularly in the detection of cancer most preferentially in human breast, stomach, and colon.Type: ApplicationFiled: May 13, 2014Publication date: September 4, 2014Applicant: ALPER BIOTECH, LLCInventor: Özge Alper
-
Publication number: 20140248673Abstract: This document describes biochemical pathways for producing pimelic acid, 7-hydroxyheptanoic acid, 7-aminoheptanoic acid, heptamethylenediamine or 1,7-heptanediol by forming two terminal functional groups, comprised of carboxyl, amine or hydroxyl group, in a C7 aliphatic backbone substrate. These pathways, metabolic engineering and cultivation strategies described herein rely on the CoA-dependent elongation enzymes or analog enzymes associated with the carbon storage pathways from polyhydroxyalkanoate accumulating bacteria.Type: ApplicationFiled: December 13, 2013Publication date: September 4, 2014Applicant: INVISTA North America S.á r.I.Inventors: Adriana Leonora Botes, Alex Van Eck Conradie
-
Publication number: 20140248663Abstract: Provided are isolated polypeptides having cellobiohydrolase activity, catalytic domains and cellulose binding domains, and polynucleotides encoding the polypeptides, catalytic domains or cellulose binding domains. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or cellulose binding domains.Type: ApplicationFiled: November 15, 2012Publication date: September 4, 2014Inventors: Lan Tang, Junxin Duan, Yu Zhang, Ye Liu
-
Publication number: 20140248397Abstract: A variant polypeptide having alpha-amylase activity, wherein the variant has an amino acid sequence which, when aligned with the alpha-amylase comprising the sequence set out in SEQ ID NO: 2, comprises at least one substitution of an amino acid residue corresponding to any of amino acids 4, 6, 13, 14, 15, 16, 20, 45, 47, 51, 54, 61, 68, 69, 70, 71, 72, 73, 74, 75, 77, 78, 80, 82, 87, 88, 94, 95, 100, 103, 104, 117, 124, 125, 126, 128, 130, 133, 134, 136, 143, 144, 146, 168, 174, 177, 178, 183, 186, 188, 189, 190, 194, 195, 199, 200, 201, 204, 207, 210, 214, 217, 219, 222, 225, 227, 233, 234, 235, 236, 240, 251, 252, 254, 258, 259, 260, 261, 262, 263, 264, 266, 267, 269, 271, 273, 281, 282, 283, 284, 286, 288, 299, 322, 323, 325, 327, 328, 331, 334, 350, 356, 358, 367, 370, 371, 374, 377, 378, 388, 391, 414, 421, 422, 445, 450, 467, 488, 505, 536, 548, 583, 588, 603, 637, 648, 651, 652, 660, 676, 677, said positions being defined with reference to SEQ ID NO: 2 and wherein the variant has one or more altered prType: ApplicationFiled: March 15, 2013Publication date: September 4, 2014Applicant: DSM IP ASSETS B.V.Inventors: Rene Marcel DE JONG, Hanna Elisabet ABBAS
-
Publication number: 20140242655Abstract: Embodiments of the present invention relate to methods for the biosynthesis of di- or trifunctional C7 alkanes in the presence of isolated enzymes or in the presence of a recombinant host cell expressing those enzymes. The di- or trifunctional C7 alkanes are useful as intermediates in the production of nylon-7, nylon-7,x, nylon-x,7, and polyesters.Type: ApplicationFiled: June 29, 2012Publication date: August 28, 2014Applicant: INVISTA TECHNOLOGIES S.A R.L.Inventors: Paul S. Pearlman, Changlin Chen, Adriana Leonora Botes, Alex Van Eck Conradie, Benjamin D. Herzog
-
Publication number: 20140242692Abstract: The present invention relates to cellular proteins that are involved in toxicity and infection or are otherwise associated with the life cycle of one or more pathogens.Type: ApplicationFiled: December 11, 2011Publication date: August 28, 2014Inventors: Donald Rubin, Dana Borden Lacy
-
Publication number: 20140234906Abstract: The present invention relates to alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: ApplicationFiled: October 17, 2012Publication date: August 21, 2014Inventors: Carsten Andersen, Signe Eskildsen Larsen, Esben Peter Friis, Peter Kamp Hansen, Henrik Friis Madsen, Anders Viksoe Nielsen, Pernille Ollendorf Micheelsen
-
Publication number: 20140234897Abstract: Disclosed are isolated polypeptides having cellobiohydrolase activity, catalytic domains, carbohydrate binding domains and polynucleotides encoding the polypeptides, catalytic domains or carbohydrate binding domains. Furthermore, nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or carbohydrate binding domains are disclosed.Type: ApplicationFiled: November 2, 2012Publication date: August 21, 2014Inventors: Yu Zhang, Junxin Duan, Ye Liu, Lan Tang
-
Publication number: 20140234214Abstract: The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.Type: ApplicationFiled: January 14, 2014Publication date: August 21, 2014Applicant: iPierian, Inc.Inventors: Irene Griswold-Prenner, Nancy E. Stagliano, Vu Dang
-
Publication number: 20140234907Abstract: Provided are isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 16, 2012Publication date: August 21, 2014Applicant: Novozymes Inc.Inventors: Yu Zhang, Ye Liu, Junxin Duan, Lan Tang
-
Publication number: 20140234313Abstract: The invention relates generally to polypeptides, such as antibody molecules, that demonstrate high stability and solubility. In particular, the invention relates to polypeptides comprising paired VL and VH domains that demonstrate soluble expression and folding in a reducing or intracellular environment. The invention also relates to polynucleotides encoding such polypeptides, to libraries of such polypeptides or polynucleotides, and to methods of using such polypeptides in research, diagnostic and therapeutic applications.Type: ApplicationFiled: February 14, 2014Publication date: August 21, 2014Applicant: Affinity Biosciences Pty LtdInventors: Matthew David Beasley, Keith Philip Niven, Ben Ross Kiefel
-
Publication number: 20140234924Abstract: The present invention provides methods of designing and generating glycerol dehydrogenase (GlyDH) variants that have altered function as compared to a parent polypeptide. The present invention further provides nucleic acids encoding GlyDH polypeptide variants having altered function as compared to the parent polypeptide. Host cells comprising polynucleotides encoding GlyDH variants and methods of producing lactic acids are also provided in various aspects of the invention.Type: ApplicationFiled: October 4, 2012Publication date: August 21, 2014Inventors: Qingzhao Wang, Keelnatham T. Shanmugam, Lonnie O'Neal Ingram
-
Publication number: 20140234918Abstract: The present invention relates to isolated polypeptides having peroxygenase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: August 10, 2012Publication date: August 21, 2014Applicant: Novozymes A/SInventors: Sara Landvik, Lars Henrik Oestergaard, Lisbeth Kalum
-
Publication number: 20140235476Abstract: Provided are protein, nucleic acid, and cellular libraries of multivalent binding proteins (e.g., DVD-Fab or DVD-Ig molecules) and the use of these libraries for the screening of multivalent binding proteins using cell surface display technology (e.g., yeast display).Type: ApplicationFiled: December 27, 2013Publication date: August 21, 2014Applicant: AbbVie, Inc.Inventors: Jijie GU, Maria Cristina HARRIS, Lorenzo BENATUIL, Chung-Ming HSIEH
-
Publication number: 20140234902Abstract: Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar, if not substantially identical, to their human counterparts. The lower eukaryotes, which ordinarily produce high-mannose containing N-glycans, including unicellular and multicellular fungi are modified to produce N-glycans such as Man5GlcNAc2 or other structures along human glycosylation pathways.Type: ApplicationFiled: May 7, 2014Publication date: August 21, 2014Applicant: GlycoFi, Inc.Inventor: Tillman U. Gerngross
-
Publication number: 20140227754Abstract: The present disclosure relates to variants of a parent glucoamylase having altered properties (e.g., improved thermostability and/or specific activity). In particular, the present disclosure provides compositions comprising the variant glucoamylases, including starch hydrolyzing compositions and cleaning compositions. The disclosure also relates to DNA constructs encoding the variants and methods of producing the glucoamylase variants in host cells.Type: ApplicationFiled: February 4, 2014Publication date: August 14, 2014Applicant: Danisco US Inc.Inventors: Wolfgang Aehle, Richard R. Bott, Martijn Scheffers, Pieter van Solingen, Casper Vroemen
-
Publication number: 20140227273Abstract: Described are proteinaceous molecules comprising at least two, preferably three to six, binding domains that bind specifically to at least two different binding sites on aberrant cells. These multi-domain and multi-specific binding molecules are preferably used in selectively modulating biological processes. The provided binding molecules are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers and autoimmune diseases.Type: ApplicationFiled: September 26, 2012Publication date: August 14, 2014Applicant: APO-TB.V.Inventors: Ralph Alexander Willemsen, Johan Renes
-
Publication number: 20140230096Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: June 24, 2013Publication date: August 14, 2014Applicant: Novozymes Inc.Inventor: Nikolaj Spodsberg
-
Publication number: 20140230097Abstract: The present invention relates to isolated polypeptides having xylanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: June 24, 2013Publication date: August 14, 2014Inventor: Nikolaj Spodsberg
-
Publication number: 20140230098Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: June 27, 2013Publication date: August 14, 2014Inventor: Nikolaj Spodsberg
-
Publication number: 20140227739Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: February 12, 2013Publication date: August 14, 2014Inventor: Nikolaj Spodsberg
-
Publication number: 20140220635Abstract: The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: ApplicationFiled: October 17, 2012Publication date: August 7, 2014Applicant: Novozymes A/SInventors: Carsten Andersen, Signe Larsen, Esben Peter Friis, Pernille Ollendorff Micheelsen, Anders Viksoe Nielsen, Randall Deinhammer, Xinyu Shen
-
Publication number: 20140220648Abstract: The invention relates to the production of aromatic molecules in prokaryotic and eukaryotic hosts such as E. coli, yeasts, filamentous fungi, algae, microalgae, other plant cells.Type: ApplicationFiled: June 22, 2012Publication date: August 7, 2014Applicant: RHO RenewablesInventor: Philip J. Barr
-
Publication number: 20140220040Abstract: Anti-LRP6 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. These anti-LRP6 antibodies can be used to enhance Wnt activity and/or antagonize Dkk1 activity. Also described are methods of therapy using such antibodies and antigen-binding regions to bind modulate Wnt/LRP6 signaling to promote tissue homeostasis, regeneration and repair in diseases such as, but not limited to, bone disorders, such as osteoporosis, rheumatoid arthritis, and osteolytic lesions caused by osteoarthritis and multiple myeloma, gastrointestinal disease and wound healing.Type: ApplicationFiled: April 17, 2014Publication date: August 7, 2014Applicant: ARCA BIOPHARMA, INC.Inventors: Arie Abo, Minke Binnerts
-
Publication number: 20140221621Abstract: Provided are protein, nucleic acid, and cellular libraries of single chain multivalent binding proteins (e.g., scDVD and scDVDFab molecules) and methods of using these of these libraries for the screening of single chain multivalent binding proteins using cell surface display technology (e.g., yeast display).Type: ApplicationFiled: December 27, 2013Publication date: August 7, 2014Applicant: AbbVie, Inc.Inventors: Lorenzo BENATUIL, Chung-Ming HSIEH
-
Patent number: 8795992Abstract: Increasing tolerance to butanol in yeast has been accomplished by increasing activity of the cell wall integrity pathway. Yeast with increased expression of SLT2p, a mitogen activated protein kinase of the MAPK module of the cell wall integrity pathway had increased tolerance to isobutanol. These yeast may be used for improved butanol production.Type: GrantFiled: December 21, 2009Date of Patent: August 5, 2014Assignee: Butamax Advanced Biofuels LLCInventors: Michael G. Bramucci, Robert A. Larossa, Dana R. Smulski
-
Patent number: 8795998Abstract: The present invention relates to a yeast cell, in particular a recombinant yeast cell, the cell lacking enzymatic activity needed for the NADH-dependent glycerol synthesis or the cell having a reduced enzymatic activity with respect to the NADH-dependent glycerol synthesis compared to its corresponding wild-type yeast cell, the cell comprising one or more heterologous nucleic acid sequences encoding an NAD+-dependent acetylating acetaldehyde dehydrogenase (EC 1.2.1.10) activity. The invention further relates to the use of a cell according to the invention in the preparation of ethanol.Type: GrantFiled: July 23, 2010Date of Patent: August 5, 2014Assignee: Technische Universiteit DelftInventors: Jacobus Thomas Pronk, Antonius Jeroen Adriaan Van Maris, Victor Gabriel Guadalupe Medina
-
Publication number: 20140212953Abstract: The present invention relates to recombinant microorganisms comprising biosynthetic pathways and methods of using said recombinant microorganisms to produce various beneficial metabolites. In various aspects of the invention, the recombinant microorganisms may further comprise one or more modifications resulting in the reduction or elimination of 3 keto-acid (e.g., acetolactate and 2-aceto-2-hydroxybutyrate) and/or aldehyde-derived by-products. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces Glade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.Type: ApplicationFiled: September 19, 2013Publication date: July 31, 2014Applicant: GEVO, Inc.Inventors: Thomas BUELTER, Andrew Hawkins, Stephanie Porter-Scheinman, Peter Meinhold, Catherine Asleson Dundon, Aristos Aristidou, Jun Urano, Doug Lies, Matthew Peters, Melissa Dey, Justas Jancauskas, Kent Evans, Julie Kelly, Ruth Berry